NCT00700206
Telik
Myelodysplastic Syndrome (MDS)
May 2008
Phase 2
NCT00280631
Telik
Myelodysplastic Syndrome (MDS)
February 2006
Phase 1-Phase 2
NCT00035867
Telik
Myelodysplastic Syndromes
April 2002
Phase 1-Phase 2
View MoreCollapse
References
[1]. Galili N, et al. Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome. J Hematol Oncol. 2012 May 6;5:20.
"目錄號(hào): HY-13634A metabolic Enzyme/Protease - Ezatiostat 是一種 glutathione 類(lèi)似物,為谷胱甘肽 S-轉(zhuǎn)移酶 P1-1 (GSTP1-1) 抑制劑。 Gutathione S-transferase 相關(guān)產(chǎn)品 Ezatiostat hydrochloride - 生物活性 Description Ezatiostat is a glutathione analog inhibitor of glutathione S-transferase P1-1 (GSTP1-1). In Vitro Ezatiostat causes dissociation of the enzyme from the jun-N-terminal kinase/c-Jun (JNK/JUN) complex, leading to JNK activation by phosphorylation. The therapeutic action of ezatiostat appears to include both proliferation of normal myeloid progenitors as well as apoptosis of the malignant clone[1]. Clinical Trial NCT01422486 Telik Myelodysplastic Syndrome (MDS) October 2011 Phase 2 NCT01459159 Telik Myelodysplastic Syndrome (MDS) October 2011 Phase 2 NCT00909584 Telik Severe Chronic Neutropenia April 2009 Phase 2 NCT01062152 Telik Myelodysplastic Syndrome November 2009 Phase 1 NCT00701870 Telik Non-small Cell Lung Cancer October 2008 Phase 2 |